Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardant HealthMEX:GH 13 ROC (Joel Greenblatt) % is -145.15% as of Mar. 2026. GuruFocus rates MEX:GH with a GF Score™ of 13/100 and a GF Value™ of MXN989.11 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Guardant Health ranks worse than 74.41% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Guardant Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -145.15%.
The historical rank and industry rank for Guardant Health's ROC (Joel Greenblatt) % or its related term are showing as below:
MEX:GH'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -521.84 Med: -183.27 Max: -118.32
Current: -137.59
During the past 10 years, Guardant Health's highest ROC (Joel Greenblatt) % was -118.32%. The lowest was -521.84%. And the median was -183.27%.
MEX:GH's ROC (Joel Greenblatt) % is ranked worse than 74.41% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs MEX:GH: -137.59
Guardant Health's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 8.80% per year.
Guardant Health (MEX:GH) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Guardant Health ROC (Joel Greenblatt) % Related Terms
Guardant Health ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Guardant Health's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GH vs LH, DGX, MEDP: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Guardant Health's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Guardant Health's ROC (Joel Greenblatt) % falls into.
Guardant Health ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -145.15% mean?
Guardant Health (MEX:GH) has a ROC (Joel Greenblatt) % of -145.15% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #157 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 74.4%.
Is Guardant Health's ROC (Joel Greenblatt) % too high?
Guardant Health's current ROC (Joel Greenblatt) % is -145.15%. Based on the distribution chart, Guardant Health ranks #157 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Guardant Health has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's ROC (Joel Greenblatt) % compare to LH and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #157 out of 211 companies for ROC (Joel Greenblatt) %. This places Guardant Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Guardant Health and its competitors. Guardant Health's current ROC (Joel Greenblatt) % is -145.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (MEX:GH) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN989.11, compared to a current price of MXN2,590.00 — trading 161.9% above its estimated fair value. The current ROC (Joel Greenblatt) % is -145.15%. Guardant Health's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current ROC (Joel Greenblatt) % is -145.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (MEX:GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of MXN2,590.00 is trading 161.9% above its estimated GF Value™ of MXN989.11.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for MEX:GH:
ROC (Joel Greenblatt) %: -145.15%
GF Value™: MXN989.11 vs. price of MXN2,590.00 (161.9% above fair value)
No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score
Get the complete analysis for MEX:GH
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GH has been successfully added to your 
